Antiretroviral treatment update from the 17th International AIDS Conference.
Boyle
Brian
B
ViralEd LLC, Stockton, NJ, USA.
Cohen
Cal
C
DeJesus
Edwin
E
Elion
Richard
R
Frank
Ian
I
Moyle
Graeme
G
Sax
Paul
P
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use; D065100:CCR5 Receptor Antagonists; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003510:Cyclohexanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D000077592:Maraviroc; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D019428:HIV Integrase Inhibitors; D011760:Pyrrolidinones; D018894:Reverse Transcriptase Inhibitors; D014230:Triazoles; D000068898:Raltegravir Potassium; D000077592:Maraviroc